Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. (Q40827632)

24 September 2017

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. (English)

1 reference

24 September 2017

1 reference

11

1 reference

24 September 2017

12

1 reference

24 September 2017

Mäkinen T

1

1 reference

24 September 2017

Jussila L

2

1 reference

24 September 2017

Veikkola T

3

1 reference

24 September 2017

Karpanen T

4

1 reference

24 September 2017

Kettunen MI

5

1 reference

24 September 2017

Pulkkanen KJ

6

1 reference

24 September 2017

Kauppinen R

7

1 reference

24 September 2017

Jackson DG

8

1 reference

24 September 2017

Kubo H

9

1 reference

24 September 2017

Nishikawa S

10

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

24 September 2017

1 reference

24 September 2017

7

1 reference

24 September 2017

2

1 reference

24 September 2017

199-205

1 reference

https://scigraph.springernature.com/pub.10.1038/84651

24 September 2017

0 references

cites work

Molecular and biological properties of vascular endothelial growth factor

1 reference

7 January 2021

Mechanisms of angiogenesis and arteriogenesis

1 reference

7 January 2021

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

7 January 2021

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

1 reference

7 January 2021

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

1 reference

7 January 2021

VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues

1 reference

7 January 2021

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

1 reference

7 January 2021

VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane

1 reference

7 January 2021

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema

1 reference

7 January 2021

Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase

1 reference

7 January 2021

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

1 reference

7 January 2021

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

1 reference

7 January 2021

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

1 reference

7 January 2021

Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor

1 reference

7 January 2021

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

7 January 2021

Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.

1 reference

7 January 2021

LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan

1 reference

7 January 2021

Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1

1 reference

7 January 2021

1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis.

1 reference

7 January 2021

Molecular regulation of lymphangiogenesis and targets for tissue oedema

1 reference

7 January 2021

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

1 reference

7 January 2021

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

1 reference

7 January 2021

Vascular endothelial growth factor C induces angiogenesis in vivo.

1 reference

7 January 2021

Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia

1 reference

7 January 2021

c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.

1 reference

7 January 2021

A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities

1 reference

7 January 2021

Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors

1 reference

7 January 2021

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer

1 reference

7 January 2021

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors

1 reference

7 January 2021

Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

1 reference

7 January 2021

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis

1 reference

7 January 2021

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

1 reference

7 January 2021

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

1 reference

7 January 2021

Identifiers

DOI

10.1038/84651

1 reference

24 September 2017

1 reference